Article and Video CATEGORIES

Cancer Journey

Search By

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
Author
GRACE Videos and Articles

ASCO 2015 Highlights 02

 

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?

[powerpress]

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Next Previous link

Previous PostNext Post